Isoquinolinones and quinolinones as modulators of polrmt
AssigneePretzel Therapeutics, Inc.
InventorsGabriel Martinez Botella, Jeremy Green, Paul S. Charifson, Simon Giroux, Andrew Griffin
Life of this patent
Estimating the term…
Abstract
The present invention provides novel isoquinolinone and quinolinone compounds that are inhibitors of mitochondrial RNA polymerase for treating various diseases such as cancer and others associated with metabolic disorders and mitochondrial dysfunction.
Claims20
A compound of formula (I), or a pharmaceutically acceptable salt thereof:
- wherein:
- Z is O, C(H)(R1), C6H4, C(O), C(O)N(R7), or N(R2);
- W is C3-C8 cycloalkyl, C4-C12 bicyclic, C4-C10 cycloalkenyl, C6-C12 aryl, or 5- to 12-membered heteroaryl, any of which is substituted with one or more groups, each independently selected from the group consisting of fluoro, chloro, trifluoromethyl, difluoromethyl, cyano, hydroxyl, C1-C4 alkoxyl, and C1-C4 alkyl optionally substituted with one or more deuterium or hydroxyl;
- R is hydrogen, or C1-C6 alkyl optionally substituted with one or more groups each independently selected from the group consisting of fluoro, hydroxyl, C1-C4 alkoxyl, cyano, C1-C4 haloalkoxyl, carboxyl, C(O)NR5R6, NR5R6 and NR2R3,
- or R is C6-C12 aryl optionally substituted with one or more groups, each independently selected from the group consisting of fluoro, chloro, C1-C4 alkyl, trifluoromethyl, difluoromethyl, cyano, hydroxyl, NR5R6, and C1-C4 alkoxyl,
- or R is hydroxyl, NR1R2, C(O)R3, C1-C4 haloalkoxyl, CH2CH2R8, CR3R4C(O)OR5, or 4-7 membered cyclic ring containing one or more heteroatoms, such cyclic ring is optionally substituted with C(O)R1, NR1—C(O)—R1, or CR3R4C(O)NR5R6;
- each R1 is independently hydrogen, C1-C4 alkoxyl, or C1-C4 alkyl optionally substituted with one or more fluoro groups;
- each R2 is independently hydrogen, C1-C4 alkyl optionally substituted with one or more fluoro groups, C(O)C1-C4 alkyl optionally substituted with one or more fluoro or methoxyl groups, C(O)-cycloheteroalkyl optionally substituted with methyl or acetate, or C(O)NHC1-C4 alkyl optionally substituted with one or more fluoro groups;
- R3 and R4 are each independently hydrogen or C1-C4 alkyl optionally substituted with one or more groups each independently selected from the group consisting of fluoro, hydroxyl, C1-C4 alkoxyl, C1-C4 haloalkoxyl, and NR5R6;
- R5 and R6 are each independently hydrogen, cycloheteroalkyl optionally substituted with acetate, or C1-C4 alkyl optionally substituted with one or more groups each independently selected from the group consisting of fluoro, hydroxyl, cyano, C1-C4 alkoxyl, C1-C4 haloalkoxyl, and NR1R2,
- or if R5 and R6 are attached to the same nitrogen atom, R5 and R6 together with their connecting nitrogen form a 3- to 7-membered heterocyclic ring or 6- to 12-membered heterobicyclic ring, each such heterocyclic ring or heterobicyclic ring optionally containing another heteroatom that is N, O, S, S(O), SO2R1, or S(O)(NR1) and each such heterocyclic ring or heterobicyclic ring is optionally substituted with one or more groups each independently selected from the group consisting of fluoro, chloro, and C1-C4 alkyl optionally substituted with one or more fluoro, C1-alkoxyl or hydroxyl, and each such heterocyclic ring or heterobicyclic ring is further optionally substituted with cycloalkyl, cyano, carboxyl, C(O)R1, C(O)NR1R2, imine, oxo, NR1—C(O)—R1, SO2R1, or C1-C4 alkylcarboxylate;
- R7 is H or C1-C6 alkyl;
- and
- R8 is aryl optionally substituted with one or more groups, each independently selected from the group consisting of fluoro, chloro, C1-C4 alkyl, trifluoromethyl, difluoromethyl, cyano, hydroxyl, and C1-C4 alkoxyl,
- or R8 is OR1, NR1R2, C(O)R1, or C(O)NR2R2.
A compound, or a pharmaceutically acceptable salt thereof, selected from the group consisting of:
A method of inhibiting the activity of POLRMT with a compound of formula (I), or a pharmaceutically acceptable salt thereof:
- wherein:
- Z is O, C(H)(R1), C6H4, C(O), C(O)N(R7), or N(R2);
- W is C3-C8 cycloalkyl, C4-C12 bicyclic, C4-C10 cycloalkenyl, C6-C12 aryl, or 5- to 12-membered heteroaryl, any of which is substituted with one or more groups, each independently selected from the group consisting of fluoro, chloro, trifluoromethyl, difluoromethyl, cyano, hydroxyl, C1-C4 alkoxyl, and C1-C4 alkyl optionally substituted with one or more deuterium or hydroxyl;
- R is hydrogen, or C1-C6 alkyl optionally substituted with one or more groups each independently selected from the group consisting of fluoro, hydroxyl, C1-C4 alkoxyl, cyano, C1-C4 haloalkoxyl, carboxyl, C(O)NR5R6, NR5R6 and NR2R3,
- or R is C6-C12 aryl optionally substituted with one or more groups, each independently selected from the group consisting of fluoro, chloro, C1-C4 alkyl, trifluoromethyl, difluoromethyl, cyano, hydroxyl, NR5R6, and C1-C4 alkoxyl,
- or R is hydroxyl, NR1R2, C(O)R3, C1-C4 haloalkoxyl, CH2CH2R8, CR3R4C(O)OR5, or 4-7 membered cyclic ring containing one or more heteroatoms, such cyclic ring is optionally substituted with C(O)R1, NR1—C(O)—R1, or CR3R4C(O)NR5R6;
- each R1 is independently hydrogen, C1-C4 alkoxyl, or C1-C4 alkyl optionally substituted with one or more fluoro groups;
- each R2 is independently hydrogen, C1-C4 alkyl optionally substituted with one or more fluoro groups, C(O)C1-C4 alkyl optionally substituted with one or more fluoro or methoxyl groups, C(O)-cycloheteroalkyl optionally substituted with methyl or acetate, or C(O)NHC1-C4 alkyl optionally substituted with one or more fluoro groups;
- R3 and R4 are each independently hydrogen or C1-C4 alkyl optionally substituted with one or more groups each independently selected from the group consisting of fluoro, hydroxyl, C1-C4 alkoxyl, C1-C4 haloalkoxyl, and NR5R6;
- R5 and R6 are each independently hydrogen or C1-C4 alkyl optionally substituted with one or more groups each independently selected from the group consisting of fluoro, hydroxyl, cyano, C1-C4 alkoxyl, C1-C4 haloalkoxyl, and NR1R2;
- or if R5 and R6 are attached to the same nitrogen atom, R5 and R6 together with their connecting nitrogen form a 3- to 7-membered heterocyclic ring or 6- to 12-membered heterobicyclic ring, each such heterocyclic ring or heterobicyclic ring optionally containing another heteroatom that is N, O, S, S(O), SO2R1, or S(O)(NR1) and each such heterocyclic ring or heterobicyclic ring is optionally substituted with one or more groups each independently selected from the group consisting of fluoro, chloro, and C1-C4 alkyl optionally substituted with one or more fluoro, C1-alkoxyl or hydroxyl, and each such heterocyclic ring or heterobicyclic ring is further optionally substituted with cycloalkyl, cyano, carboxyl, C(O)R1, C(O)NR1R2, imine, oxo, NR1—C(O)—R1, SO2R1, or C1-C4 alkylcarboxylate;
- and
- R7 is H or C1-C6 alkyl;
- and
- R8 is aryl optionally substituted with one or more groups, each independently selected from the group consisting of fluoro, chloro, C1-C4 alkyl, trifluoromethyl, difluoromethyl, cyano, hydroxyl, and C1-C4 alkoxyl, or R8 is OR1, NR1R2, C(O)R1, or C(O)NR2R2.
Dependencies are inferred from the claim text.